An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study
- First Online:
- Cite this article as:
- Wu, A.Y.T., Kong, N.C.T., de Leon, F.A. et al. Diabetologia (2005) 48: 17. doi:10.1007/s00125-004-1599-9
- 2.1k Downloads
Microalbuminuria represents the earliest clinical evidence of diabetic nephropathy and is a marker of increased cardiovascular morbidity and mortality. Its early detection allows the implementation of individualised and aggressive intervention programmes to reduce cardiovascular risk factors. There is limited information on the prevalence of microalbuminuria among hypertensive type 2 diabetic patients in Asia.
This cross-sectional epidemiological study aimed to assess the prevalence of microalbuminuria and macroalbuminuria among consecutively screened hypertensive type 2 diabetic adult patients in 103 centres in 10 Asian countries or regions. Predictive factors for microalbuminuria and macroalbuminuria were characterised using a stepwise logistic regression model.
A total of 6,801 patients were enrolled and 5,549 patients constituted the per-protocol population (patients with bacteriuria and haematuria were excluded). The prevalence of microalbuminuria was 39.8% (39.2–40.5; 95% CI) and the prevalence of macroalbuminuria was 18.8% (18.2–19.3; 95% CI). Only 11.6% of the patients had systolic and diastolic blood pressure below the 130/80 mm Hg target. In the multivariate analyses, the predictive factors for the presence of microalbuminuria were age, BMI, systolic blood pressure and ethnic origin. The highlighted predictive factors for the presence of macroalbuminuria were age, sex, ethnic origin, BMI, duration of diabetes, presence of diabetic complications, intake of diuretics, intake of calcium channel blockers, diastolic and systolic blood pressure.
The high prevalence (58.6%) of micro or macroalbuminuria observed in these patients is alarming and indicates an impending pandemic of diabetic cardiovascular and renal diseases in Asia with its potential economic consequences.
American Diabetes Association
angiotensin receptor blocker
MicroAlbuminuria Prevalence Study
Hypertension is common among patients with type 2 diabetes, with a prevalence approximately twice that of the nondiabetic population, and may precede the onset of diabetes . The prevalence of hypertension is further increased in patients with type 2 diabetes mellitus and elevated AER, compared with patients with type 2 diabetes mellitus and no evidence of renal involvement. The higher the systolic blood pressure, the greater the absolute excess cardiovascular risk for diabetic patients, indicating a greater potential for preventing cardiovascular death by control of elevated blood pressure . Ageing of the population and an increasing prevalence of obesity and sedentary life habits are leading to an greater prevalence of diabetes, particularly in Asia . By 2025, the World Health Organization predicts that the number of patients with the disease worldwide will increase to 300 million. Half will be Asian. Southeast Asia will have the highest rate of diabetes worldwide .
Because of the adverse impact of microalbuminuria (MAU) on survival in patients with type 2 diabetes mellitus and the renal risk of macroalbuminuria [5–8], screening and intervention programmes should be implemented early, at the stage of microalbuminuria. Annual screening for microalbuminuria is recommended by the American Diabetes Association (ADA) , as a high proportion of patients with type 2 diabetes are found to have MAU or overt nephropathy shortly after diagnosis of their diabetes. Screening by means of a semiquantitative dipstick test is easy, immediate and accurate .
To date there have been few studies in Asian populations on the prevalence of MAU [11–14]. These studies have only explored the percentage of MAU in diabetic or hypertensive patients. The MicroAlbuminuria Prevalence Study (MAPS) is the first large study to evaluate the prevalence of micro and macroalbuminuria in high-risk patients with type 2 diabetes mellitus and hypertension.
Subjects and methods
Patients and study design
Outpatients who were above the age of 18, from different Asian ethnic subgroups, and had previously diagnosed hypertension (treated or untreated) and type 2 diabetes mellitus (treated or untreated) were consecutively screened at each participating centre. Previously diagnosed hypertension and diabetes were historically defined as mentioned in the patient medical record and verified during monitoring visits. The only exclusion criterion was previously known macroalbuminuria. Patient data included ethnic origin; past medical and family history; onset dates of hypertension and diabetes; current diabetes status with known complications such as retinopathy, peripheral neuropathy, cardiovascular disease as reported during the interview, as well as glycaemic control (latest values of fasting blood glucose and HbA1c if available); current hypertensive status (mean of two consecutive measurements of office supine systolic and diastolic blood pressure) and current therapy; and dyslipidaemic status (known or previously diagnosed dyslipidaemia), with latest blood tests results if available, and use of lipid-lowering agents. A single urine specimen was collected in disposable plastic vessels.
The primary study objective was to assess the prevalence of microalbuminuria and macroalbuminuria. Secondary objectives aimed to assess the routine blood pressure control level, to collect the associated cardiovascular risk factors and diabetic complications, and to characterise the predictive factors for micro and macroalbuminuria.
Informed consent was obtained from all participants. The protocol was approved by the Ethics Committees in countries where it was required by the regulatory bodies. The study was supervised by a multidisciplinary steering committee. The committee designed the study, interpreted the data and wrote the article.
A two-step MAU screening process was conducted. First, the detection of macroalbuminuria was carried out by trained personnel on fresh urine (first morning or random morning specimens) using a visual colorimetric semiquantitative urine test strip (Nephur 7 Test, Roche Diagnostics, Mannheim, Germany). The test strip also allowed quantification of pH, urine glucose, ketones bodies, leucocytes, nitrites, and blood. If specimens were negative for albumin, detection of microalbuminuria was performed on the same urine with a second specific semiquantitative urine test strip (Micral-test, Roche Diagnostics). The intensity of the colour produced was visually compared with the reference chart on the Micral-test bottle (0, 20, 50, 100 mg/l, >100 mg/l). A measurement of 20 mg/l or above was considered positive. Specificity, sensitivity, positive and negative predictive values of the second test strip were determined according to the manufacturer’s evaluation report and with a cutoff point set at 20 mg/l. Results were: sensitivity 90.1%, specificity 87.2%, positive predictive value 0.82, negative predictive value 0.93.
Between January 2002 and December 2002 we recruited 6,801 patients from 103 medical centres (30 general practitioner and primary care clinics, 19 general hospital outpatient clinics, 40 diabetic centres, and 14 cardiology or nephrology centres) throughout ten Asian countries or regions (China, Hong Kong, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan and Thailand).
Quantitative variables were described by their means, standard deviations, and counts. Median and quartiles 1 and 3 were reported when appropriate. Qualitative variables were described by counts and percentages, missing data were included in the calculation of percentages. The three albuminuric subgroups were compared by one-way ANOVA for quantitative variables and by a chi square test for sex. The significance level was fixed at 5%. Prevalence rates were calculated with a two-sided 95% CI. A two-step logistic regression analysis was performed on the per-protocol population. First, a univariate analysis determined the links between microalbuminuria (Yes/No) or macroalbuminuria (Yes/No) and the following 17 variables: ethnic subgroup, sex, age group, BMI, duration of diabetes classes, duration of hypertension classes, systolic blood pressure by class (high normal/mild/moderate/severe/very severe) based on the 1999 WHO/ISH classification , diastolic blood pressure by class, cardiovascular complications (Yes/No), diabetic complications (Yes/No), smoking (Yes/No), diuretic intake (Yes/No), α blocker (Yes/No), β blocker (Yes/No), calcium channel blocker (Yes/No), ACE inhibitor (Yes/No), and angiotensin II receptor blockers (ARB) intake (Yes/No). A link between two variables was considered significant if the p value test was 0.25 or less. Then, a stepwise logistic regression that only included the significant variables determined the best model to predict microalbuminuria or macroalbuminuria. All analyses were performed using SAS software version 8.02.
Patient characteristics and family history in the per-protocol population
Men, n (%)
Women, n (%)
Mean age in years (SD)
62.3 (10.8), n=1,041
61.3 (10.6), n=2,210
60.3 (10.1), n=2,296
61.1 (10.4), n=5,547
Mean height in cm (SD)
159.8 (8.2), n=1,033
160.0 (8.8), n=2,206
160.0 (8.5), n=2,289
160.0 (8.5), n=5,528
Mean weight in kg (SD)
65. 5 (12.4), n=1,038
65.9 (12.4), n=2,209
64.6 (11.4), n=2,291
65.3 (12.0), n=5,538
Mean BMI in kg/m2 (SD)
25.6 (4.2), n=1,032
25.7 (4.0), n=2,204
25.2 (3.7), n=2,285
25.5 (3.9), n=5,521
History of diabetes
History of hypertension
History of cardiovascular disease
Description of type 2 diabetes mellitus in the per-protocol population
Duration of diabetes (years)
At least 1 diabetic complication
Known cardiovascular complications
At least 1 cardiovascular complication
Congestive heart failure
Mean fasting blood glucose in mmol/l (SD)
8.9 (3.4), n=937
8.5 (3.1), n=2,013
8.1 (2.9), n=2,128
8.4 (3.1), n=5,078
Mean HbA1c values in % (SD)
8.2 (1.9), n=541
7.9 (1.8), n=1,297
7.6 (1.8), n=1,466
7.8 (1.8), n=3,304
Mean serum creatinine in μmol/l (SD)
103.7 (49.9), n=707
85.3 (26.9), n=1,554
83.4 (25.2), n=1,723
87.7 (32.5), n=3,984
Description of hypertension in the per-protocol population
Duration of hypertension (years)
Mean systolic blood pressure in mm Hg (SD)
148.3 (21.0), n=1,040
142.9 (17.9), n=2,206
140.0 (17.6), n=2,292
142.7 (18.7), n=5,538
Systolic blood pressure by class
≤130 mm Hg (normal)
>130–139 (high normal)
>209 (very severe)
Mean diastolic blood pressure in mm Hg (SD)
85.0 (10.9), n=1,040
83.3 (10.2), n=2,206
82.0 (9.9), n=2,291
83.1 (10.3), n=5,537
Diastolic blood pressure by class
≤85 mm Hg (normal)
>85–89 (high normal)
>119 (very severe)
Systolic/diastolic blood pressure
<130/80 mm Hg
Predictive factors for the presence of microalbuminuria (odds ratio and 95% CI)a
Odds ratio CI
Age (vs. [30, 49] years, n=635)
SBP levels (vs. normal, n=1,449), mm Hg
Ethnic subgroup (vs. Chinese, n=2,935)
Predictive factors for the presence of macroalbuminuria (odds ratio and 95% CI)a
Odds ratio CI
Diuretic (Yes vs. No) (n=580/2,758)
Calcium channel blocker (Yes vs. No) (n=1,221/2,117)
DBP levels (vs. normal, n=2,082)
>89–99 mm Hg (n=1,317)
>119 mm Hg (n=17)
Sex (men vs. women) (n=1,434/1,904)
Diabetic complication (Yes vs. No) (n=971/2,366)
Age (vs. [30, 49] years, n=451)
Duration of diabetes subgroups (vs. ≤1 year, n=771)
>5–10 years (n=776)
>10 years (n=793)
Ethnic subgroup (vs. Chinese, n=2,130)
SBP levels (vs. normal, n=1,033)
>130–139 mm Hg (n=418)
>139–159 mm Hg (n=1,247)
>159–179 mm Hg (n=490)
>179–209 mm Hg (n=127)
>209 mm Hg (n=17)
MAPS is the first large multicentre epidemiological study in Asia to determine the prevalence of microalbuminuria in type 2 diabetic patients with hypertension. This study indicates that 39.8% of the analysable population of 5,549 patients have microalbuminuria. This is higher than the prevalence rates, reported in population-based studies  for Western diabetic patients, which range from 17% to 21%. In another Asian study, microalbuminuria was detected in 36.3% of type 2 diabetics at a diabetes centre in southern India . The wide range in the prevalence of microalbuminuria in type 2 diabetics is probably due to genetic and cardiovascular risk factors (blood pressure, cholesterol, salt intake, etc.). In MAPS, most of the patients were Chinese (64%). Compared to patients of Chinese origin, patients of Korean and Malay ethnic origin were most likely to have microalbuminuria. The high prevalence of microalbuminuria in non-Caucasians has also been observed in the Pima Indians of North America, where type 2 diabetes is very common, and more than 50% develop proteinuria within 20 years . In type 2 diabetes, microalbuminuria is often associated with clustering of cardiovascular risk factors to form the metabolic syndrome . High prevalence of metabolic syndrome has been reported in Asia [19, 20] with early onset of metabolic syndrome and diabetes mellitus in Asian Indians [19, 21]. In our study, over 48% of the patients had a known dyslipidaemia. Hypertriglyceridaemia, hypercholesterolaemia, high LDL cholesterol and low HDL cholesterol levels were reported among 58%, 63%, 42%, and 23% of these patients, respectively. Drug therapy of dyslipidaemia was suboptimal as only 40% of patients were receiving a lipid-lowering agent.
In addition to the 39.8% prevalence rate of microalbuminuria, 18.8% of 5,549 patients were found to have macroalbuminuria. As patients with previously known diabetic nephropathy or macroalbuminuria were excluded from screening, this high rate of macroalbuminuria was not anticipated and raises important questions about current screening strategies in diabetic patients.
There are a few limitations to the study results. Firstly, MAU detection was based on a single urine spot collection with semiquantitative dipstick determinations. The ADA guidelines  acknowledge that this technique has acceptable sensitivity and specificity, but recommend that positive tests be reconfirmed with more specific methods and, due to the marked day-to-day variability, that several collections be done in a 3- to 6-month period before designating a patient as having MAU. In this large cross-sectional epidemiological study, the single urine collection and semiquantitative determination was judged adequate for the study objectives. Moreover, a within-trial validation of the Micral-test was performed by one of the authors (C.Y. Pan) in China. Micral-test results of 119 consecutive MAPS patients were compared with those obtained by immunochemical assay (DCA 2000+ commercial kit, Bayer Diagnostics, Germany) and 56 samples were compared with immunoturbidimetric determination (Beckman Array 360 system, USA). In comparison with DCA 2000+ (albumin/creatinine ratio), the Micral-test had an overall sensitivity of 91.9% and specificity of 63.4%. In comparison with immunoturbidimetric assay, the overall sensitivity and specificity of the Micral-test was 95% and 80%, respectively.
Another possible limitation is that this was not a real population-based study. The extrapolation of these findings to the global type 2 diabetic and hypertensive population should be carefully evaluated. Nevertheless, at the study level, all efforts were made to have a balanced distribution between patients enrolled by diabetologists (47%) and by non-diabetes specialists (53%). And, at the country level, only representative physicians experienced in managing type 2 diabetic patients were selected and consecutive patients enrolled.
A third limitation concerns the blood test values as no systematic blood sampling was required per protocol. Only documented previous blood test results were recorded. For glycaemic control, 93.9% and 59.7% of patients had documented values of blood glucose and HbA1c, respectively. For serum lipids, the available data rate varied between 72.8% (LDL cholesterol) and 81.6% of patients (triglycerides) with previously known dyslipidaemia. Importantly, the rates of available data were similar among the three subgroups.
Hypertension is common among diabetic patients and the prevalence is further increased in the presence of renal disease . In MAPS, the mean blood pressure level was 143/83 mm Hg and the mean duration of hypertension was 8.5 years. Systolic blood pressure was predictive of both microalbuminuria and macroalbuminuria. The presence of diabetic complications, duration of diabetes, and types of antihypertensive agent, i.e., diuretics and calcium channel blockers, were also predictive of macroalbuminuria. Although no conclusions could be drawn from a cross-sectional study, these predictors are probably indicative of more severe underlying blood pressure elevation, and it is consistent with previous reports that dihydropyridine calcium channel blockers are not as effective as ACE inhibitors or ARB in alleviating albuminuria [23, 24]. Only 10.6% of patients with microalbuminuria and 8.2% with macroalbuminuria achieved blood pressure lower than 130/80 mm Hg. Eleven percent of our patients did not receive any antihypertensive therapy. The low control rates observed in this analysis reflect the prescribing habits of doctors in Asia, their perception of target blood pressure levels and the influence of guidelines in managing hypertension. These low control rates are not substantially different from many western countries . As expected, severely elevated systolic blood pressure (>179 mm Hg) was more common in the macroalbuminuric group. It is therefore important to develop strategies that increase the percentage of patients who achieve optimal blood pressure control as Asian type 2 diabetic patients have a higher risk of renal complications and stroke than their Caucasian counterparts .
Optimal blood pressure, tight glycaemic control and pharmacological blockade of the renin–angiotensin system with ACE inhibitors or ARB have been shown to decrease AER and decrease progression from incipient to overt nephropathy [23, 27]. In the IRMA 2 study (“Irbesartan microalbuminuria type 2 diabetes mellitus in hypertensive patients”), hypertensive type 2 diabetic patients with microalbuminuria taking irbesartan 300 mg daily had a significant (70%, p<0.001) relative risk reduction for the development of diabetic nephropathy as measured by the changes in AER . The RENAAL and IDNT trials have conclusively demonstrated the advantage of ARB therapy (losartan 100 mg or irbesartan 300 mg) as part of a multidrug strategy to lower blood pressure and to prevent doubling of serum creatinine, end-stage renal disease or death in type 2 diabetic patients with hypertension and macroalbuminuria [23, 27]. There is compelling evidence that therapy that negatively modulates the renin–angiotensin system may be especially effective in reducing renal and cardiovascular disease in diabetic patients with hypertension. In the MAPS evaluation, ACE inhibitors and ARB were used in only 43.9% and 19.2% of patients, respectively. Less than 50% of patients were receiving two or more antihypertensive agents, even though a number of clinical trials have confirmed the need for multidrug therapies to reach target blood pressure in diabetes [29, 30].
Glycaemic control has been shown to prevent development of nephropathy and to reverse established pathology . However, the majority of our patients in the microalbuminuric and macroalbuminuric groups did not achieve adequate glycaemic control as evidenced by available mean HbA1c values of over 7%.
In conclusion, a 39.8% prevalence rate of microalbuminuria was observed in Asian type 2 diabetic and hypertensive patients. This high prevalence is alarming and indicates an impending pandemic of diabetic cardiovascular and renal disease in Asia with its potential economical burden. We strongly recommend implementing screening programmes for microalbuminuria in type 2 diabetic patients. Through cardiovascular risk reduction, lowering of blood pressure, renin–angiotensin system blockade and glycaemic control such early and targeted intervention could significantly reduce the occurrence of cardiovascular and renal complications.
We would like to thank the 103 investigators and the monitoring teams of the ten participating countries and regions for their contribution to the study. This work was supported by a grant from Sanofi-Synthelabo.